Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia

Journal of Neurology

Volumn 252, Issue 9, 2005, Pages 1108-1114

  Van Der Worp, H Bart ^a   De Haan, Peter ^b   Morrema, Erik ^a   Kalkman, Cor J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Animal models; Cerebral ischaemia; Methodological quality; Neuroprotection; Review

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; CLOMETHIAZOLE; GAVESTINEL; LUBELUZOLE; TIRILAZAD;

ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; MEDICAL LITERATURE; METHODOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN;

EID: 25144439926     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0802-3     Document Type: Article

References (37)

1. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015-1020
2. Bath PM, Iddenden R, Bath FJ, Orgogozo J-M, Tirilazad International Steering Committee (2001) Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev CD002087
3. Bebarta V, Luyten D, Heard K (2003) Emergency medicine animal research: Does use of randomization and blinding affect the results? Acad Emerg Med 10:684-687
4. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 349:1641-1649
5. Chang ML, Yang J, Kem S, Klaidman L, Sugawara T, Chan PH, Adams JD Jr (2002) Nicotinamide and ketamine reduce infarct volume and DNA fragmentation in rats after brain ischemia and reperfusion. Neurosci Lett 322:137-140
6. Drummond JC, Piyash PM, Kimbro JR (2000) Neuroprotection failure in stroke. Lancet 356:1032-1033
7. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867-872
8. Festing MF (2003) Principles: the need for better experimental design. Trends Pharmacol Sci 24:341-345
9. Fisher M (2003) Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke 34:1539-1546
10. Gandolfo C, Sandercock P, Conti M (2002) Lubeluzole for acute ischaemic stroke. Cochrane Database Syst Rev CD001924
11. Gladstone DJ, Black SE, Hakim AM, Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery (2002) Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123-2136
12. Grotta J (1995) Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy. J Intern Med 237:89-94
13. Grotta J (2001) Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 33:306-307
14. Haelewyn B, Yvon A, Hanouz JL, MacKenzie ET, Ducouret P, Gerard JL, Roussel S (2003) Desflurane affords greater protection than halothane against focal cerebral ischaemia in the rat. Br J Anaesth 91:390-396
15. Hankey GJ (2002) Clomethiazole: an unsuccessful bachelor, but perhaps a properous married man? Stroke 33:128-129
16. Horn J, de Haan RJ, Vermeulen M, Luiten PGM, Limburg M (2001) Nimodipine in animal model experiments of focal cerebral ischemia. Stroke 32:2433-2438
17. International Stroke Trial Collaborative Group (1997) The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, or both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581
18. Ioannidis JPA, Haidich A-B, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J (2001) Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286:821-830
19. Kawaguchi M, Kimbro JR, Drummond JC, Cole DJ, Kelly PJ, Patel PM (2000) Isoflurane delays but does not prevent cerebral infarction in rats subjected to focal ischemia. Anesthesiol 92:1335-1342
20. th century. Stroke 32:1349-1359
21. Lees KR (2002) Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke 33:308-309
22. Lees KR, Asplund K, Carolei A, Davis SM, Diener H-C, Kaste M, Orgogozo J-M, Whitehead J, for the GAIN International Investigators (2000) Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 355:1949-1954
23. Lees KR, Hankey GJ, Hacke W (2003) Design of future acute-stroke treatment trials. Lancet Neurol 2:54-61
24. Liebeskind DS, Kasner SE (2001) Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs 15:165-174
25. Macleod MR, O'Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35:1203-1208
26. Miettinen OS (1983) The need for randomisation in the study of intended effects. Stat Med 2:267-271
27. Muir KW, Lees KR (2003) Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev CD001244
28. Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, The RANTTAS Investigators (1999) Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. Stroke 30:293-298
29. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412
30. Schulz KF, Grimes DA (2002) Blinding in randomised trials: hiding who got what. Lancet 359:696-700
31. Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758
32. Stroke Therapy Academic Industry Roundtable II (STAIR II) (2001) Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32:1598-1606
33. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group (2000) Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31:2912-2919
34. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
35. Van der Worp HB, Rappelle LJ (1998) Complications of acute ischaemic stroke. Cerebrovasc Dis 8:124-132
36. Wardlaw JM, Warlow CP, Sandercock PAG, Dennis MS, Lindley RI (2000) Neuroprotection disappointment yet aGAIN. Lancet 356:597
37. Weir CJ, Kaste M, Lees KR (2004) Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke 35:2111-2116